Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lumiera Health Inc. (V:NHP)

Business Focus: Pharmaceuticals (NEC)

Jul 05, 2022 01:50 pm ET
Lumiera reports first half of 2022 results with a 40% increase compared to previous year
MONTREAL, July 5, 2022 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to provide an update to announce that the corporate strategy and plans that were put place in 2021, are continuing to prove successful with Lumiera's first half of 2022 improving its sales by +40% compared to last year first half results.
Jun 09, 2022 09:00 am ET
Lumiera Health launches US sales of Awaye pain relief cream with first shipment to Amazon.com
MONTREAL, June 9, 2022 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the launch of its Awaye™ pain relief cream in the US market. The first shipment of Awaye™ has been sent to Amazon.com's distribution center and will soon be available to American consumers.
Jun 01, 2022 01:53 pm ET
Lumiera reports second quarter 2022 results with a 28% increase compared to previous year
MONTREAL, June 1, 2022 /CNW/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to provide an update to announce that the corporate strategy and plans that were put place in 2021, are continuing to prove successful with Lumiera's fiscal Q2'22 being another strong quarter with sales +28% vs Q2 2021.
May 26, 2022 08:30 am ET
Lumiera Health expands retail footprint of Awaye™ pain relief across Quebec with Sobeys' Rachelle Béry
MONTREAL, May 26, 2022 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the retail expansion of its Awaye™ pain relief cream.  Awaye™ is now available at Rachelle Béry health food stores. Rachelle Béry, is a natural health food chain part of Sobeys Inc.'s retail network.
May 20, 2022 01:15 pm ET
Lumiera announces the results of its annual meeting
MONTREAL, May 20, 2022 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting"), which was held May 19, 2022 by webcast. All of the nominees listed in the Company's management information circular dated April 14, 2022, were elected as directors.
May 04, 2022 03:26 pm ET
Lumiera Health files new NPN application with Health Canada to extend Awaye Pain Relief product line
MONTREAL, May 4, 2022 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce it has filed for a new NPN application with Health Canada, as it prepares to extend its Awaye Pain Relief product line. The new product, Awaye Sport with menthol, will cater to pain sufferers looking for a cooling relief effect, which represents an additional consumer segment for the Awaye brand. This also represents the first innovation in Awaye's planned development pipeline.
Mar 31, 2022 10:46 am ET
Lumiera Health expands online distribution with Bazzzics™ sleep-aids on Amazon and Well.ca
MONTREAL, March 31, 2022 /CNW/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the expansion of its online distribution with the launch of the company's Bazzzics™ line of natural sleep-aids on Amazon Canada. The Company has also successfully listed Bazzzics™ on Well.ca, one of Canada's leading e-commerce retailer in the Health & Wellness sector.
Mar 24, 2022 10:25 am ET
Lumiera Health signs distribution agreement to launch Awaye™ in Vietnam - a market of 100 million people
MONTREAL, March 24, 2022 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the signing of a distribution agreement with Fideschem International Ltd., a Singapore-based company that will enable Awaye™ to access the Vietnamese market which has a population of approximately 100 million people and a pain relief market forecasted to grow at >11.24% annually for the foreseeable future. 
Mar 22, 2022 09:20 am ET
Lumiera begins fiscal year strong with +25% growth in Q1 2022 compared to previous year
MONTREAL, March 22, 2022 /CNW/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to provide an update to announce that the corporate strategy and plans that were put place in 2021, are continuing to prove successful with Lumiera's fiscal Q1'22 being another strong quarter with sales +25% vs Q1 2021.
Mar 08, 2022 10:00 am ET
Lumiera Health signs definitive agreement to launch Awaye™ in the US and receives NDC from FDA
MONTREAL, March 8, 2022 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of evidence-based botanical products, is pleased to announce two significant milestones on the path to Awaye™ sales in the United States. 
Feb 25, 2022 02:45 pm ET
Lumiera Health changes their debt structure to allocate more cash for accelerated growth
MONTREAL, Feb. 25, 2022 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce that it has entered into an amending agreement with its third party lender in respect of the outstanding Note, the principal amount of which currently stands at $1,325,000.
Feb 22, 2022 11:33 am ET
As part of US expansion plans Lumiera Health Appoints Jacqueline Khayat to Board of Directors
MONTREAL, Feb. 22, 2022 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce that Jacqueline Khayat has been appointed to the Board of Directors of the Company.
Feb 15, 2022 07:00 am ET
Lumiera Health signs binding term sheet to launch Awaye™ pain relief cream in the US
MONTREAL, Feb. 15, 2022 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of evidence-based botanical products, is pleased to announce the signing of a binding term sheet with Pain Level LLC, a NY-based broker. Pain Level LLC will be representing the company's Awaye™ pain relief product in the Northeastern US market. In addition to managing sales initiatives and the distribution network, the group will be responsible for executing the advertising and marketing programs in their territory, which covers
Dec 02, 2021 04:55 pm ET
The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing their latest press releases.
Dec 02, 2021 09:03 am ET
Lumiera ends fiscal year strong with sales in November 2021 up 59% compared to November 2020
MONTREAL, Dec. 2, 2021 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to provide an update to announce that the new corporate strategy and plans that were put in place Q1-Q3 2021 have been successful.  Lumiera's fiscal Q4 was a record quarter with sales +30% vs Q4 2020, highlighted by November which was a record sale month, +59.3% over November 2020.
Nov 18, 2021 02:30 pm ET
Lumiera Health Appoints Louis Doyle to Board of Directors
MONTREAL, Nov. 18, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce that Louis Doyle has been appointed to the Board of Directors of the Company following the resignation of Nathalie Nasseri as a director of the Company.
Oct 19, 2021 07:00 am ET
Lumiera's new first of its kind pain relief cream, Awaye™, activates the body's cannabinoid type 2 receptors to decrease pain and inflammation.
Awaye™ is a unique over-the-counter pain relief cream made from natural active ingredients Awaye™ is clinically tested, non-addictive pain relief product developed and made in Canada MONTREAL, Oct. 19, 2021 /CNW/ - Canadians struggling with chronic pain have a new therapeutic option called Awaye™, a first of its kind therapy that leverages the body's own pain-defense mechanism, also known as the endo-cannabinoid system. Developed by Canadian-based Lumiera Health Innovation, and approved by Health Canada as a natural health product, Awaye™ is indicated for those suffering from painful strain
Oct 08, 2021 11:45 am ET
Lumiera Health announces launch of its new Direct-to-Consumer platform
MONTREAL, Oct. 8, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, has announced the launch of its new direct-to-consumer e-commerce platform, Holizen.com. The site will offer Canadian consumers the opportunity to purchase on-trend products from the Holizen Brand, including its collection of health tonics and supplements, its Bazzzics line of sleep-aids and ayurvedic medicine products among others, all delivered right to their homes.
Sep 14, 2021 04:26 pm ET
Lumiera Health announces Private Placement Extension
MONTREAL, Sept. 14, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera ") The TSX-V exchange has approved a 30 day extension to close the private placement announced on August 6, 2021 to raise up to $900,000. The private placement units ("Unit") are priced at $0.03 per Unit. Each Unit will consist of one common share in the capital of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Common Share, at an exercise price of $0.06 per share, for a period of four ye
Aug 20, 2021 03:15 pm ET
Lumiera Health begins sales of Awaye™ pain relief cream on Amazon marketplace
MONTREAL, Aug. 20, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce that it has received approval to sell topical products on the Amazon platform and that its Awaye™ Pain Relief Cream has been sent to Amazon's fulfillment center and is now available for sale to customers across Canada.
Aug 06, 2021 12:30 pm ET
Lumiera Health announces proposed $900,000 Private Placement
MONTREAL, Aug. 6, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is announcing that it intends to sell, on a private placement basis, up to 30,000,000 units (the "Units") at a price of $0.03 per Unit, for gross proceeds to the Company of up to $900,000. The issue price of the Units is equal to the closing price of the Lumiera shares on the TSX Venture Exchange on August 5, 2021.
Jul 12, 2021 05:57 pm ET
Lumiera Health announces closing of $1.3 Million private placement
MONTREAL, July 12, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce that it has closed its previously announced non-brokered private placement ("Private Placement"). The Private Placement consisted of the issuance of 52,000,000 Units (the "Units") at a price of $0.025 per Unit for gross proceeds of $1.3 million.
Jul 06, 2021 06:36 pm ET
Lumiera announces the results of its annual meeting
MONTREAL, July 6, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting"), which was held June 30, 2021 by webcast. All of the nominees listed in the Company's management information circular dated May 21, 2021, were elected as directors.
Jun 18, 2021 08:10 am ET
Lumiera Health announces proposed $1.3 Million Private Placement
MONTREAL, June 18, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is announcing that it intends to sell, on a private placement basis, in one or more tranches, up to 52,000,000 units (the "Units") at a price of $0.025 per Unit, for gross proceeds to the Company of up to $1.3 million. The issue price of the Units is equal to the closing price of the Lumiera shares on the TSX Venture Exchange on June 17, 2021.
May 20, 2021 08:00 am ET
Lumiera Health expands distribution of Bazzzics™ sleep-aid products nationally
MONTREAL, May 20, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of evidence-based botanical products, is pleased to announce that it has signed an agreement with Vancouver based Ecotrend Ecologics ("Ecotrend") for the national distribution of Bazzzics™, a natural health product line made with a proprietary blend of plant-based extracts that have demonstrated efficacy for sleep and anxiety disorders.
Apr 15, 2021 08:00 am ET
Lumiera Health begins sales of Awaye™ pain relief cream and launches direct-to-consumer e-Commerce platform
MONTREAL, April 15, 2021 /CNW/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of evidence-based botanical products for the healthcare industry, is pleased to announce the launch of Awaye™ pain relief cream for the Canadian market. Awaye™ provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the endocannabinoid system, the body's built in pain and inflammation defense system. Awaye™ is a unique Health Canada approved topical cream that provides relief from pain throug
Mar 16, 2021 10:33 pm ET
9315-4466 Québec Inc. Disposes of Shares in Lumiera Health Inc.
BOUCHERVILLE, QC, March 16, 2021 /CNW Telbec/ - 9315-4466 Québec Inc. (the "Corporation"), a corporation controlled by Dr. Guy Chamberland, has disposed of 105,000 common shares of Lumiera Health Inc. ("Lumiera"), representing approximately 0.10% of the presently issued and outstanding common shares of Lumiera.
Mar 12, 2021 07:00 am ET
Shares for Debt Settlement
MONTREAL, March 12, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of evidence-based botanical products for the healthcare industry, is pleased to announce that the annual consolidated financial statements and management's discussion and analysis for the year ended November 30, 2020 have been approved at the Board of Directors meeting ("Board") which was held on March 10, 2021 and have now been published on SEDAR.
Feb 04, 2021 08:00 am ET
Carlos Ponce is Appointed New Chief Executive Officer
MONTREAL, Feb. 4, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), is pleased to announce the appointment of Carlos Ponce, a successful entrepreneur, innovator and brand builder in the natural health and wellness industry, as its Chief Executive Officer.
Jan 29, 2021 07:00 am ET
Lumiera Announces Completion of the Sales of Its Non-Core Asset Celext07
MONTREAL, Jan. 29, 2021 /CNW Telbec/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), is pleased to announce that effective on January 1st, 2020, it has completed its previously announced sale of its non-core asset Celext07 to BioSun Products Inc. ("Biosun") for a cash consideration of $350,000 received at closing yesterday (the "Transaction").  As part of the Transaction, Lumiera also secured a right of first consideration on any products that could be commercialized, on a worldwide basis, as a natural health product.
Jan 04, 2021 07:00 am ET
Lumiera Monetizes Its Non-Core Asset with the Sale of Celext07
Strengthen the focus of the Company toward natural health products base assets Cash transaction representing a non-dilutive financing of $350,000 Sale of the non-core asset Celext07, a natural biostimulant and biopesticide with agricultural applications Right of first refusal on potential natural health products developed by the buyer using Celext07 MONTREAL, Jan. 4, 2021 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), today announces the signing of a binding term sheet pursuant to which the Company will sell its non-core asset Celext07 to BioSun Products Inc. ("Bios
Nov 09, 2020 07:00 am ET
Lumiera Announces the Signature of a Sale Representation Agreement Covering Quebec and Canada for its Holizen Portfolio
MONTREAL, Nov. 9, 2020 /CNW/ - Lumiera Health Inc.  (TSXV: NHP) (the "Company" or "Lumiera "), formerly known as Mondias Natural Products Inc., is happy to announce the signature of a sale representation contract with Quebec Contact Inc. for its portfolio of natural health products Holizen Laboratories.
Nov 04, 2020 04:00 pm ET
Mondias Announces Name Change following Acquisition of Lumiera Acquisition and Closing of Private Placement
MONTREAL, Nov. 4, 2020 /CNW Telbec/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") is pleased to announce that the Company will change its corporate name to Lumiera Health Inc. / Lumiera Santé Inc. effective as of November 5, 2020, following the acquisition of Lumiera Health Innovation Inc. on October 27, 2020 (the "Lumiera Acquisition", announced here),
Oct 28, 2020 08:00 am ET
Mondias Announces Completion of Lumiera Health Acquisition
MONTREAL, Oct. 28, 2020 /CNW Telbec/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") is pleased to announce that effective October 27, 2020, it completed its previously announced (here, and here) acquisition of Lumiera Health Innovation Inc. ("Lumiera"), a former subsidiary of Tetra Bio-Pharma Inc. ("Tetra") (the "Lumiera Acquisition"). The parties received conditional approval from the TSX Venture Exchange ("TSXV") for the Lumiera Acquisition and related matters described below. The Lumiera Acquisition and other transactions described herein remain subject to fina
Oct 23, 2020 08:00 am ET
Mondias announces amendments to the terms of previously announced acquisition of Lumiera Health Innovation Inc.
MONTREAL, Oct. 23, 2020 /CNW Telbec/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") announces that it has agreed to amend certain terms of its proposed acquisition of Lumiera Health Innovation Inc. ("Lumiera"), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra"), as previously announced on July 23, 2020 (here) (the "Proposed Transaction").
Sep 23, 2020 04:30 pm ET
Mondias announces Debt Conversion Settlements
MONTREAL, Sept. 23, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") announces that it intends to settle a total of CAD$919,647 of debt (the "Debt") owed to certain (i) directors of the Company to whom director fees are owed, (ii) debenture holders of the Company who have elected to convert their debentures, (iii) holders of Preferred Class E and Preferred Class I who have requested that the Company redeem their shares, and (iv) private lenders of the Company (each a "Creditor") (the "Shares for Debt Settlements").  The Company will settle the Debt by iss
Sep 14, 2020 04:47 pm ET
Mondias announces the results of its annual meeting
MONTREAL, Sept. 14, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting"), which was held earlier today by webcast. All of the nominees listed in the Company's management information circular dated August 14, 2020, were elected as directors.
Aug 17, 2020 08:30 am ET
Tetra Bio-Pharma and Mondias enter into final agreement for the purchase of Lumiera Health Innovation Inc.
MONTREAL, Aug. 17, 2020 /CNW Telbec/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture markets and Tetra Bio-Pharma Inc. (TSX: TBP) ("Tetra"), a biopharmaceutical leader in the discovery and development of cannabinoid-derived therapeutics are pleased to announce they are entering into Definitive Agreement for the purchase of Lumiera Health Innovation Inc. ("Lumiera") as previously announced on July 23, 2020. The agreement will be submitted to Mondias Annual General and Special Meeti
Aug 05, 2020 04:30 pm ET
Mario Paradis is named Interim CEO
MONTREAL, Aug. 5, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") announces that Mario Paradis will assume starting today, on an interim basis, the role of Chief Executive Officer. The Company anticipates that Mr. Paradis will continue as interim CEO until the planned acquisition of Lumiera Health Innovation Inc., a subsidiary of Tetra Bio-Pharma, as announced on July 23rd, is completed.
Jul 23, 2020 11:18 am ET
IIROC Trading Resumption - NHP
VANCOUVER, BC, July 23, 2020 /CNW/ - Trading resumes in:
Jul 23, 2020 10:30 am ET
Tetra and Mondias jointly announce the acquisition of Tetra's subsidiary, Lumiera, by Mondias to create a new growth platform
Allowing Tetra to focus on its core business of developing proprietary and scientifically validated cannabinoid-based medicines to relieve symptoms associated with advanced cancer pain, chronic pain (cancer and non-cancer pain) and ophthalmic disease. Significantly expands addressable markets, positioning Mondias to play broader role in natural health products industry Complementary businesses with practically no product overlap MONTREAL, July 23, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the heal
Jul 23, 2020 08:15 am ET
IIROC Trading Halt - NHP
VANCOUVER, BC, July 23, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 16, 2020 04:30 pm ET
Mondias Announces Warrants extension and repricing
MONTREAL, June 16, 2020 /CNW/ – Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture today announces that it is proposing to extend the expiry dates and alter the exercise price of all share purchase warrants (the "Warrants"). These Warrants were originally issued following a private placement of Element 79, and then reissued following the qualifying transaction. On November 26, 2018, the Company extended its 6,882,760 warrants for a period of 1 year. As a result, the new maturity date o
May 06, 2020 04:30 pm ET
Mondias terminates the acquisition of the assets of Erablier inc.
MONTREAL, May 6, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") has decided to terminate the acquisition of substantially all the assets of Erablier Inc. that was previously announced on March 19th, 2020.
Apr 08, 2020 08:00 am ET
Normand Drolet is named new Executive Chairman and change in the management
MONTREAL, April 8, 2020 /CNW/ - Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias ") is pleased to announce the nomination of Normand Drolet as Executive Chairman of the Board. Normand Drolet will also assume, on an interim basis, the role of Chief Executive Officer.  
Mar 26, 2020 08:42 am ET
Mondias Announces Successful Completion of CELEXT07 Evaluation with Premier Tech
Parties Agree to Extend Research to Focus on Medicinal Crop
Mar 19, 2020 05:01 pm ET
Mondias Announces Definitive Agreement to Acquire Assets of Érablier Inc. Premium Organic Maple Water Beverages
Company Enters Functional Beverages Market with Plant-Based Water Products
Feb 18, 2020 07:35 am ET
Mondias Announces New Chief Financial Officer
Establishing an Experienced Management Team for Growth
Feb 05, 2020 07:43 am ET
Mondias Signs Binding LOI to Acquire Premium Organic Maple Water Beverage Products
First Acquisition for Wholly Owned SetPoint Beverages Business Unit
Feb 04, 2020 07:33 am ET
Mondias Completes Unsecured Convertible Debenture Financing
MONTREAL, Feb. 4, 2020 /CNW/ - Mondias Natural Products Inc. (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based botanical products for the healthcare and bio-agriculture markets, today announced that it has closed its non-brokered financing of unsecured convertible debentures in the principal amount of C$425,000 (the "Debentures").
Jan 30, 2020 07:34 am ET
Jan 13, 2020 11:02 am ET
Mondias Naturals Announces Update on Unsecured Convertible Debenture Financing
MONTREAL, Jan. 13, 2020 /CNW/ – Mondias Natural Products Inc.  (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based botanical products for the healthcare and bio-agriculture markets, today announces that it is extending the close of its non-brokered financing of unsecured convertible debentures in the principal amount of CAD$500,000, as previously disclosed on a November 28, 2019, news release, to January 15, 2020.  All of the previously disclosed terms of the financing remain unchanged.
Dec 19, 2019 07:49 am ET
Mondias Naturals Launches Its Bazzzics™ line of Natural Sleep Aid Products
Company Unveils New Eco-Responsible Consumer Packaging and Enters eRetail Market
Dec 17, 2019 03:21 pm ET
Mondias Naturals Names New Member to its Board of Directors
Company Preparing for Accelerated Expansion
Nov 28, 2019 04:00 pm ET
Mondias Naturals Announces Unsecured Convertible Debenture Financing
MONTREAL, Nov. 28, 2019 /CNW/ - Mondias Natural Products Inc. (TSXV: NHP) (the "Company" or "Mondias") specializing in evidence-based botanical products for the healthcare and bio-agriculture markets, today announces that it is arranging a non-brokered financing of unsecured convertible debentures in the principal amount of CAD$500,000. The Company will use the proceeds to implement a digital marketing campaign, launch new natural health products, further pursue strategic partnerships and for general corporate purposes. The Offering of the Debentures is subject to the receipt of all necessar
Nov 18, 2019 07:00 am ET
Mondias Naturals Receives Mitacs Funding for the Botanical Product CELEXT07
Research to be Conducted at McGill University to Study CELEXT07 and the Role of Functional Microbiome in Cannabis Breeding Strategies Against Biotic Stress
Sep 23, 2019 09:01 am ET
Aug 20, 2019 08:32 am ET
Mondias Naturals Announces the Appointment of Dr. Patrick Frankham as Chief Executive Officer
Company to benefit from Dr. Frankham's strong commercial and scientific expertise in developing and marketing biopharmaceutical and natural health products
Jul 23, 2019 08:22 am ET
Mondias CELEXT07 selected by MontVert.com
CELEXT07 biostimulant enhances grass fertilization and growth
Jul 02, 2019 08:40 am ET
Mondias retains Paradox for Investor Relations
MONTREAL, July 2, 2019 /CNW Telbec/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce that it has retained the services of Relations Publiques Paradox Inc. ("Paradox") to provide investor relations services for the Company, effective July 1, 2019. Paradox is a Montreal-based investor relations consultancy firm that has been in business for 20 years. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.
Jun 11, 2019 08:45 am ET
Mondias announces the results of its annual meeting
MONTREAL, June 11, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting"), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company's management information circular dated May 6, 2019, were re-elected as directors.
May 16, 2019 08:31 am ET
Mondias CELEXT07 latest test results confirm effective suppression of grey mould on hops
Primarily used in the production of alcoholic beverages, especially beer, hops represent another large market for CELEXT07 in addition to cannabis.
May 08, 2019 08:18 am ET
Mondias strengthens its management structure
MONTREAL, May 8, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the appointment of Mr. André Rancourt as Executive Chairman, and of Mr. Derek Lindsay as Vice President, Corporate Development, effective immediately. Mr. Rancourt was previously Chairman of the Board.
Mar 18, 2019 07:00 am ET
Mondias receives positive results from greenhouse production tests conducted on CELEXT07 with leading cannabis producer
Foliar application of CELEXT07 bio-defense stimulant extract alone or in combination with a botanically-derived antimicrobial plant extract results in the prevention and suppression of powdery mildew on cannabis leaves. CELEXT07 is a strong alternative to synthetic fungicides for cannabis growers in search of eco-friendly alternatives. CELEXT07 extract is ready to market: production capacity secured to meet demand from potential clients.
Mar 13, 2019 07:00 am ET
Mondias names Jamil Samsatly as Chief Scientific Officer
MONTREAL, March 13, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the appointment of Jamil Samsatly as Chief Scientific Officer. Mr. Samsatly has been conducting research for the past two years as a consultant on the Company's CELEXT07, a bio-defense stimulant that has the potential of becoming a superior eco-friendly alternative to synthetic fungicides, as part of a collaboration project with McGill University.
Feb 12, 2019 06:30 am ET
Mondias Completes Characterization of CELEXT07 that Confirms Its Biostimulant and Antifungal Capabilities and Expands Its Global Market Potential
CELEXT07 a new botanical agent with functional role in plant physiology; Mondias to target both the biostimulation and antimicrobial agricultural market; CELEXT07 an eco-friendly agent for the cannabis industry.
Feb 11, 2019 04:00 pm ET
Mondias Announces an Amendment to its Stock Option Plan
MONTREAL, Feb. 11, 2019 /CNW Telbec/ - Mondias Natural Products Inc. (TSXV: NHP) ("Mondias" or the "Corporation"), a Corporation that specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets, announces that its Board of Directors has approved an amendment to its stock option plan to become effective upon approval by the shareholders of the Corporation at the Annual General Meeting of shareholders to be held later this year and upon receipt of final approval by the TSX Venture Exchange Inc. A copy of the pr
Jan 25, 2019 07:00 am ET
Mondias announces agreement with Wisdom of Nature Brokerage to expand retail sales in Ontario and grants stock options
Mondias continues growth of retail business across Canada and announce issuance of stock options  
Dec 05, 2018 07:00 am ET
Mondias Provides Update on Natural Fungicide Product Development & Commercialization
CELEXT07 a new botanical agent for grey mold;Mondias to target small fruit cultivation market
Nov 27, 2018 03:11 pm ET
IIROC Trading Resumption - NHP
VANCOUVER, Nov. 27, 2018 /CNW/ - Trading resumes in:
Nov 23, 2018 03:30 pm ET
Mondias Natural Products Inc. Announces Closing of Qualifying Transaction
MONTREAL, Nov. 23, 2018 /CNW/ - Mondias Natural Products Inc. (TSXV: NHP) ("Mondias" or the "Company") is pleased to announce that on November 14, 2018, it closed its previously announced transaction (the "Transaction") with Element 79 Capital Inc. ("Element").